Shares of Bluebird Bio (BLUE) and Celgene (CELG) fell Monday on concerns their jointly developed cell therapy for multiple myeloma could be threatened by a novel antibody drug that emerged from Amgen’s (AMGN) pipeline this weekend.

In an early stage clinical trial, four of five patients with multiple myeloma were treated with the Amgen therapy and had stringent “complete responses,” meaning they presented with no detectable disease. The patients, who had failed to respond to multiple lines of previous medicines, continued to show no detectable disease after 10 months of follow-up with the treatment, called AMG 420. The drug was well-tolerated.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy